“Let’s aim for helping people to live much longer than we can today. And if we only end up helping them live really well for a long time that will be great too.”
- Andrew Worden
Our Mission
Lifespan Vision Ventures invests in companies that develop therapeutics focusing on longevity and aging reversal.
​
​Our goal is to enable healthy, strong, and vibrant human lifespan past 120 years.
​
Our primary foci are the whole body, joints, heart, skin, brain, and muscles.
Value Add
-
Deep understanding of science and technology. ​
-
Ability to lead or participate in founding, seed, angel, early and mid-stage investment rounds.
-
Strong financial market contacts for obtaining working capital needed through bank lines, follow on equity and debt financings and public offerings.
-
Management has proven entrepreneurial business ability to found and lead startups that demonstrate rapid and successful growth.
-
Relationships with a wide variety of academics, professionals, and institutions allow LifeSpan to bring parties together for collaboration and to create synergy between these different parties. This can accelerate development timelines and allow for new possibilities to be uncovered.
Educational institutions attended by management
Gifts/grants to the following institutions
Our Founding Partner, Visionary:
Andrew Worden
​Connecticut, United States
Background:
Through his business ventures, Mr. Worden has gained unique insights on how to scale businesses rapidly and successfully. He has decades of experience in launching, managing, planning, analyzing, and investing with public and private companies, especially within the cleantech markets. Mr. Worden has a proven combination of understanding science, technology, and entrepreneurship.
​
Mr. Worden founded GameChange Solar in 2012 with the vision to make solar energy become the lowest cost technology for electricity generation globally. His leadership and experience led to GameChange Solar’s growth in improving technology and leveraging massive scale manufacturing to aggressively cost reduce its systems and substantially reduce the total cost of solar power plants. GameChange Solar has grown from a startup in 2012 to become a global leader with over $1 billion in profitable sales in 2022. Solar energy is now among the lowest cost for electricity generation in most world markets.
​
In 2010, prior to GameChange Solar, Mr. Worden founded Soltas Energy to develop and own solar power plants. The company built ten solar power plants which were then successfully sold by 2014.
​
Prior to 2010, Mr. Worden has decades of experience as an investor primarily with Barron Partners LP, which was a global long-only investment partnership. While managing Barron Partners LP, Mr. Worden oversaw investments in over 170 companies globally in multiple industries. Many of these companies were either public or private companies which later became public. The investments in each company ranged up to $15 million individually.
Mr. Worden was the General Partner of Barron and ultimately became the largest investor of the company. He changed his primary focus from investments to renewable energy starting with Soltas Energy and then with GameChange Solar.
​
In addition, Mr. Worden is the founder and serves as a director of the Barron Charitable Foundation, a non-profit organization dedicated to helping those in need.
​
To further his vision for longevity, Mr. Worden has established and funded research at Harvard University’s John A. Paulson School of Engineering and Applied Sciences. The Andrew Worden SEAS Dean’s Innovation Fund is dedicated to funding scientific research in cleantech, AI, medical, and other key areas.
Birthplace: Boston, Massachusetts
Education: Graduated from Harvard University with a Bachelor of Arts Degree in Physical Sciences. As a cross-enrolled undergraduate while at Harvard, Mr. Worden also studied Engineering at the Massachusetts Institute of Technology in conjunction with Finance and Marketing at MIT’s Sloan School of Business.
Harry Robb
Principal
London, England
Mr. Robb is a member of the investment team at LifeSpan Vision Ventures and brings hands-on experience in conducting comprehensive research and analysis to facilitate investment decision-making across the longevity biotech sector.
Previously, Mr. Robb served as an investment manager at Longevity.Technology, a media and investment platform dedicated to the longevity sector. In this role, he established Longevity.Technology’s global institutional and private client investor network, and oversaw deal origination, culminating in the development of a deal pipeline with an estimated value of $300 million.
While pursuing his Master of Science Degree at Imperial College London, Mr. Robb was an intern at FLYFWD Ventures and OXWASH. At FLYFWD Ventures, he assumed an investment role, while at OXWASH, he contributed to business development efforts in the field of sustainable laundry services.
Birthplace: Preston, United Kingdom
Education: Graduated from Imperial College London with a Master of Science Degree in Applied Biosciences and Biotechnology, and from King’s College London with a Bachelor of Science Degree in Biomedical Science.
Jordan B. Burton, Ph.D
Associate
California, United States
Dr. Burton drives scientific investment decisions at LifeSpan Vision Ventures, where he evaluates early-stage biotechnologies that could fundamentally alter human aging. Since joining as an Associate in 2023, he has led technical due diligence across our biotech investments, with particular expertise in genetic medicine platforms that address root causes of age-related decline. His work shapes how the fund identifies and evaluates opportunities in emerging areas like cellular reprogramming, senescent cell biology, and tissue regeneration.
​
Dr. Burton's deep understanding of aging biology enables him to identify breakthrough technologies that others might overlook - from gene therapy platforms addressing previously untreatable conditions to novel approaches for muscle wasting in the elderly. But his involvement goes beyond picking winners. He works alongside founding teams as they navigate the complex path from bench to bedside, providing scientific guidance on clinical development and facilitating partnerships with pharmaceutical companies. His work directly accelerates the development of therapies that could fundamentally change how we age.
​
Prior to venture capital, Dr. Burton's research at the Buck Institute for Research on Aging directly influenced how pharmaceutical companies approach age-related diseases. He led projects that identified new therapeutic targets for kidney disease and developed analytical frameworks that multiple biotech partners now use in their drug and biomarker discovery pipelines. This hands-on experience developing actual therapies gives him unique insight into which early-stage technologies have real potential versus those that merely sound promising on paper.
​
Dr. Burton's leadership extends beyond investment activities. He serves as Chair of the US Human Proteome Organization's Education and Outreach Committee and previously served as President of the Buck Institute Postdoctoral Association. He earned his Ph.D. in Chemistry from Wayne State University, where his participation in the Innovation Honors Program first exposed him to the challenge of moving discoveries from academic labs into the hands of patients who need them. His work at LifeSpan Vision Ventures represents the continuation of this mission - ensuring that breakthrough aging science doesn't remain trapped in research papers but becomes accessible therapies that extend human healthspan.
​
Birthplace: Sault Ste. Marie, Michigan
Education: Postdoc in Proteomics of Longevity from Buck Institute for Research on Aging
PhD in Analytical Chemistry from Wayne State University
BSc in Chemistry from Lake Superior State University
Altar Munis, PhD
Associate
Cambridge, United Kingdom
Dr. Munis is a venture capital professional with a background spanning life sciences, emerging healthcare technologies, and innovation strategy.
​
Before joining LifeSpan Vision Ventures, he completed postdoctoral research at the University of Oxford and held scientific and strategic roles at AstraZeneca and Eisai, contributing to programs across high-impact therapeutic areas including oncology, neurology, and immunology. His work combined deep scientific expertise with translational strategy, supporting early-stage research initiatives aimed at advancing novel therapeutics.
Most recently, Dr. Munis was responsible for sourcing and evaluating investment opportunities at Eisai, with a focus on life science therapeutics, techbio, and AI. His role encompassed leading due diligence activities, conducting market and competitive landscape analyses, and building strategic networks across venture capital, biotechnology, and academic ecosystems. He also supported in-licensing and partnership activities.
​
At LifeSpan Vision Ventures, Dr. Munis applies a multidisciplinary, data-driven approach to venture investing, with a particular focus on transformational science and therapies that advance regenerative medicine and promote longevity and healthy aging. He is committed to identifying and advancing disruptive technologies that will define the future of healthcare and human well-being.
Birthplace: Turkey
Education: BSc in Chemical and Biomolecular Engineering from Johns Hopkins University
PhD in Immunology and Gene Therapy from University College London
